Literature DB >> 2169649

An insertion in the human thyrotropin receptor critical for high affinity hormone binding.

H L Wadsworth1, G D Chazenbalk, Y Nagayama, D Russo, B Rapoport.   

Abstract

Thyrotropin (TSH), luteinizing hormone (LH), and chorionic gonadotropin (CG) are structurally related glycoprotein hormones, which bind to receptors that share a high degree of sequence similarity. However, comparison of the primary amino acid sequences of the TSH and LH-CG receptors reveals two unique insertions of 8 and 50 amino acids in the extracellular domain of the TSH receptor. The functional significance of these insertions were determined by site-directed mutagenesis. Deletion of the 50-amino acid tract (residues 317 to 366) had no effect on TSH binding or on TSH and thyroid-stimulating immunoglobulin (TSI) biological activities. In contrast, either deletion or substitution of the eight-amino acid region (residues 38 to 45) abolished these activities. This eight-amino acid tract near the amino terminus of the TSH receptor appears to be an important site of interaction for both TSH and TSI.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169649     DOI: 10.1126/science.2169649

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  24 in total

Review 1.  Immunity to the thyroid-stimulating hormone receptor.

Authors:  J Furmaniak; B R Smith
Journal:  Springer Semin Immunopathol       Date:  1993

2.  Unaltered thyroid function in mice responding to a highly immunogenic thyrotropin receptor: implications for the establishment of a mouse model for Graves' disease.

Authors:  G Carayanniotis; G C Huang; L B Nicholson; T Scott; P Allain; A M McGregor; J P Banga
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

3.  Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.

Authors:  I F Charo; S J Myers; A Herman; C Franci; A J Connolly; S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 4.  Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.

Authors:  Terry F Davies; Rauf Latif
Journal:  Expert Opin Ther Targets       Date:  2015-03-13       Impact factor: 6.902

Review 5.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

6.  Agonist-regulated cleavage of the extracellular domain of parathyroid hormone receptor type 1.

Authors:  Christoph Klenk; Stefan Schulz; Davide Calebiro; Martin J Lohse
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

7.  Cloning from the thyroid of a protein related to actin binding protein that is recognized by Graves disease immunoglobulins.

Authors:  P J Leedman; B Faulkner-Jones; D S Cram; P J Harrison; J West; E O'Brien; R Simpson; R L Coppel; L C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Rearrangement of the Extracellular Domain/Extracellular Loop 1 Interface Is Critical for Thyrotropin Receptor Activation.

Authors:  Joerg Schaarschmidt; Marcus B M Nagel; Sandra Huth; Holger Jaeschke; Rocco Moretti; Vera Hintze; Martin von Bergen; Stefan Kalkhof; Jens Meiler; Ralf Paschke
Journal:  J Biol Chem       Date:  2016-04-26       Impact factor: 5.157

9.  The thyrotropin receptor hinge region is not simply a scaffold for the leucine-rich domain but contributes to ligand binding and signal transduction.

Authors:  Yumiko Mizutori; Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Mol Endocrinol       Date:  2008-01-24

10.  Rhodopsin molecular evolution in mammals inhabiting low light environments.

Authors:  Huabin Zhao; Binghua Ru; Emma C Teeling; Christopher G Faulkes; Shuyi Zhang; Stephen J Rossiter
Journal:  PLoS One       Date:  2009-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.